Promitil® Overview

Lipomedix most advanced program is Promitil®, which has completed a clinical Phase 1a study in cancer patients, and a Phase 1b study in advanced colon cancer. 

A Phase 1b study to examine the safety and efficacy of Promitil-based chemo-radiotherapy in patients with advanced cancer was completed. 

A Phase 2a study to treat patients with recurrent ovarian cancer and inoperable, locally advanced or metastatic pancreatic cancer, which bears deleterious germline or somatic mutations in BRCA1, BRCA2, or HRD-related genes is ongoing. 

Further to this, Lipomedix pipeline includes two other products currently under preclinical development.

• Targeted form of Promitil® (LPMX-2) directed to folate receptors of cancer cells, for intra-vesical delivery in the treatment of superficial bladder cancer.
• A new and proprietary multidrug liposome formulation with greatly enhanced anticancer activity (LPMX-3).